This is a Phase II open-label study to assess the efficacy and safety of camizestrant (a next-generation oral selective oestrogen receptor degrader - SERD) compared to standard endocrine therapy (aromatase inhibitor or tamoxifen) for patients with early ER-positive HER2-negative breast cancer and an intermediate-to-high or high risk of recurrence and who have completed definitive locoregional treatment and have no evidence of disease.
New Zealand sites for this trial will be Auckland, Waikato and Palmerston North.
Read more about this trial here.
7 November 2024
19 June 2026 update:
Recruitment to this trial is now closed, meeting its enrolment target of 5,500 participants on 2 June. Participants enrolled in the trial are still continuing with their treatment and study visits.
